Frank Wunder

Leverkusen, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2.

Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2.

Journal: Nature communications
Published: April 02, 2024

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.

Journal: Nature cardiovascular research
Published: July 24, 2023

New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.

New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.

Journal: Journal of medicinal chemistry
Published: April 11, 2023

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2B Antagonist.

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2B Antagonist.

Journal: Journal of medicinal chemistry
Published: March 18, 2023

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.

Journal: Journal of medicinal chemistry
Published: December 08, 2022

Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.

Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.

Journal: British journal of pharmacology
Published: August 10, 2022

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

Journal: Respiratory research
Published: May 06, 2022

Establishment of a novel, cell-based autotaxin assay.

Establishment of a novel, cell-based autotaxin assay.

Journal: Analytical biochemistry
Published: June 24, 2021

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

Journal: Journal of medicinal chemistry
Published: April 19, 2021

Development of a novel, sensitive cell-based corin assay.

Development of a novel, sensitive cell-based corin assay.

Journal: Biochemical pharmacology
Published: October 31, 2018

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.

Journal: Journal of medicinal chemistry
Published: May 31, 2017

PDE2 at the crossway between cAMP and cGMP signalling in the heart.

PDE2 at the crossway between cAMP and cGMP signalling in the heart.

Journal: Cellular signalling
Published: April 13, 2017
Showing 1-12 of 20

Last Updated: 09/26/2026